ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/07/26	$0.000100	0.00%	4,102

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 23:24:48 28/07/2026 +04			5-day change	1st Jan Change
0.000100 ^USD	0.00%		0.00%	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.6M 3.36M 3.09M 5.78M 393M 5.92M 39.89M 15.6M 194M 15.4M 15.06M 672M	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-1.3M -1.14M -1.06M -975K -1.83M -124M -1.87M -12.6M -4.93M -61.42M -4.87M -4.76M -212M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
12/04/23	Insider Buy: Obseva	MT
06/04/23	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
01/04/23	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
31/03/23	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
22/03/23	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
15/03/23	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
13/03/23	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
13/03/23	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
13/03/23	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
13/03/23	ObsEva SA Announces Executive Changes	CI
03/03/23	Top Premarket Gainers	MT

30/08/22	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
01/08/22	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
29/07/22	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
03/06/22	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
26/04/22	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Stock

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news : ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Course Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
01/04/23	ObsEva Files Year End 2022 Financial Statements	GL
23/03/23	OBSEVA SA : Other Events (form 8-K)	AQ
15/03/23	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

20/04/23	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
06/04/23	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
06/04/23	Bourse Zurich: ouverture en hausse avant le long week-end pascal
01/04/23	Obseva bleibt 2022 tief in den roten Zahlen
01/04/23	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.05
3 years	0		0.4
5 years	0		3.35
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
06/04/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
28/02/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23/02/23	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	0.00%	0.00%	0.00%	-99.80%	11.72K
ARGENX SE	-1.91%	-4.57%	+45.37%	+66.43%	55.2B
WUXI APPTEC CO., LTD.	+2.83%	+0.48%	+28.18%	+82.59%	55.6B
BIONTECH SE	+0.54%	+1.22%	-16.62%	-13.47%	23.51B
INSMED INCORPORATED	-0.97%	-3.30%	-1.79%	+383.00%	22.35B
WUXI BIOLOGICS (CAYMAN) INC.	-4.01%	-3.67%	+13.17%	-14.29%	20.6B
GENMAB A/S	-0.94%	-2.78%	+26.48%	-33.58%	17.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.34%	-7.77%	+23.78%	+536.66%	15.16B
EXELIXIS, INC.	-2.09%	+0.64%	+49.78%	+178.74%	13.91B
PHARMAESSENTIA CORPORATION	-3.14%	-8.47%	+165.37%	+292.18%	13.74B
Average	-1.31%	-1.14%	+33.37%	+137.85%	23.75B
Weighted average by Cap.	-0.76%	-0.52%	+32.41%	+127.40%

	2021	2022
Net sales	-	19.64M 17.26M 16.11M 14.78M 27.67M 1.88B 28.35M 191M 74.69M 931M 73.73M 72.13M 3.22B
Net income	-58.38M -51.3M -47.88M -43.94M -82.26M -5.59B -84.28M -568M -222M -2.77B -219M -214M -9.57B	-29.88M -26.25M -24.51M -22.49M -42.1M -2.86B -43.14M -291M -114M -1.42B -112M -110M -4.9B
Net Debt	-28.08M -24.67M -23.03M -21.13M -39.56M -2.69B -40.53M -273M -107M -1.33B -105M -103M -4.6B	-5.4M -4.74M -4.43M -4.06M -7.6M -517M -7.79M -52.49M -20.53M -256M -20.26M -19.82M -884M